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Abstract
Objective: To investigate the effects of single doses of a selective serotonin
reuptake inhibitor (SSRI) on lower limb voluntary and reflex function in
individuals with chronic stroke.
Design: Double-blind, randomized, placebo-controlled crossover trial.
Setting: Outpatient research setting.
Participants: Individuals (N=10; 7 men; mean age ± SD, 57±10y) with
poststroke hemiplegia of >1 year duration who completed all assessments.
Interventions: Patients were assessed before and 5 hours after single-dose,
overencapsulated 10-mg doses of escitalopram (SSRI) or placebo, with 1
week between conditions.
Main Outcome Measures: Primary assessments included maximal ankle and
knee isometric strength, and velocity-dependent (30°/s–120°/s) plantarflexor
stretch reflexes under passive conditions, and separately during and after 3
superimposed maximal volitional drive to simulate conditions of increased
serotonin release. Secondary measures included clinical measures of lower
limb coordination and locomotion.
Results: SSRI administration significantly increased stretch reflex torques at
higher stretch velocities (eg, 90°/s; P=.03), with reflexes at lower velocities
enhanced by superimposed voluntary drive (P=.02). No significant
improvements were seen in volitional peak torques or in clinical measures of
lower limb function (lowest P=.10).
Conclusions: Increases in spasticity but not strength or lower limb function
were observed with single-dose SSRI administration in individuals with
chronic stroke. Further studies should evaluate whether repeated dosing of
SSRIs, or as combined with specific interventions, is required to elicit
significant benefit of these agents on lower limb function poststroke.
Keywords: Muscle spasticity, Muscle strength, Rehabilitation, Serotonin,
Stroke
List of abbreviations
 5-HT, 5-hydroxytryptamine (serotonin);
 MG, medial gastrocnemius;
 MVC, maximum volitional contraction;
 SCI, spinal cord injury;
 6MWD, 6-minute walking distance;
 SSRI, selective serotonin reuptake inhibitor;
 TA, tibialis anterior;
 UMN, upper motor neuron

Unilateral stroke produces the characteristic upper motor neuron
(UMN) syndrome, which includes “positive” signs of spasticity1,2 and
“negative” signs of hemiparesis3,4 and disrupted coordination.5,6 While
increased spasticity is considered a major barrier for recovery of
function,1,7,8,9 evidence suggests that weakness is the primary
determinant of motor function of both lower and upper extremities.4,10,
11,12,13
Most strategies to enhance strength poststroke focus on physical
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training and electrical stimulation paradigms, whereas pharmacologic
interventions are directed primarily to decrease spasticity14,15,16 rather
than to increase strength.
Previous data suggest that selective serotonin reuptake
inhibitors (SSRIs) may mitigate weakness17 and improve function
poststroke.18,19,20 In general, SSRIs facilitate 5-hydroxytryptamine
(serotonin) (5-HT) transmission by decreasing presynaptic
sequestration in axon terminals originating primarily from brainstem
(raphe) projections.21 Such pathways are active during wakefulness
with increased activity during rhythmic, repetitive movements such as
locomotion.22,23 While the central effects of 5-HT are complex, the net
result on motor systems is excitatory.24,25 In humans poststroke, most
studies using SSRIs or other 5-HT reuptake inhibitors (eg, fluoxetine,
paroxetine, venlafaxine) focus on the upper extremity and indicate
enhanced cortical excitability and motor performance in subacute and
chronic stroke (grip strength, rate of finger tap, and 9-hole peg
test17,20,26). Interestingly, with repeated SSRI administration, data
from intact individuals demonstrate potential decreased motor cortical
excitability,27,28 while studies19,29 with patients early poststroke
undergoing rehabilitation indicate improved motor recovery. Although
changes in lower extremity function have not been well studied
poststroke, single-dose SSRI (escitalopram) administration may
improve leg strength in chronic, incomplete spinal cord injury
(SCI).30,31
Despite the focus on increased supraspinal excitability with
SSRIs, these agents may also increase spinal excitability.32,33 For
example, longstanding and recent data in human SCI30,31,34 suggest
increased spastic motor activity after single or repeated doses of
SSRIs, although similar findings have not been reported in patients
with stroke. In 1 study,35 greater antagonist muscle activity was
observed during volitional upper extremity motor tasks after use of an
SSRI poststroke, with no changes in strength or task performance.
However, spasticity was not assessed. Whether the findings of
increased spasticity with SSRIs are selective to patients with SCI or
attributable to differences in the extremities tested is not clear.
Increased spasticity with SSRI administration poststroke may be of
interest to rehabilitation professionals because spastic hypertonia with
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UMN syndrome is still considered by many to be a major barrier to
functional recovery.8,9
The objective of this study was to determine the effects of single
SSRI doses on lower extremity motor function in patients with chronic
stroke. Using a double-blind, randomized, placebo-controlled crossover
design, we hypothesized that SSRIs would increase volitional strength
in patients with chronic hemiparesis poststroke, consistent with data
from upper extremity studies and patients with incomplete SCI. We
focused on the single-dose effects here to minimize potential
habituation with repeated SSRI use,27,28 and because of the potential
increase in spasticity that may interfere immediately with lower limb
function or patient comfort. Considering the potential effects on spinal
excitability,36,37 we also evaluated the effects of SSRIs on stretch
reflexes during passive (resting) conditions, and during and after
rhythmic, repeated volitional tasks designed to simulate conditions of
increased 5-HT release.22,23 The immediate effects of SSRIs on lower
limb motor function are of clinical interest given their common use for
treatment of depressive symptoms in this patient population,38 and the
potential consequences of altering motor function during functional
tasks.

Methods
Participants
Individuals with chronic (>1y) hemiparesis after unilateral
supratentorial stroke, and lower extremity Fugl-Meyer scores <3439
were recruited. Additional criteria included passive ankle range of
motion from 0° to 30° plantarflexion, Modified Ashworth Scale score
≥1 of the paretic plantarflexors,40 and the ability to ambulate without
physical assistance but with assistive devices and below-knee orthoses
if necessary. Exclusion criteria included use of oral antispastic
medications <14 days previously or receiving a botulinum toxin
injection <6 months ago, the presence of uncontrolled
cardiorespiratory or metabolic diseases, or having a score <23/30 on
the Mini-Mental State Examination.41 Written consent was obtained
from all subjects, with procedures approved by the local ethics
committee. A sample size of 10 individuals was targeted from previous
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findings in patients with stroke with fewer subjects (n=4–817 and 20) and
data of altered volitional strength after single-dose SSRI assessments
in human SCI.30 Power analyses from the latter data indicate that 10
subjects would provide 91% power (effect size, 1.34).

Study protocol
Subjects were randomly assigned to receive 10mg of
escitalopram on day 1 and placebo (microcrystalline cellulose) on day
2, or with the order reversed. The half-life of escitalopram is 27
hours,42 and 7 days between testing ensured drug elimination before
reassessment. Agents were overencapsulated and block randomized (4
subjects per block) by the pharmacist who maintained blinding.
Subjects were tested before and 4 to 5 hours after drug administration
(time for peak plasma concentration42). Testing was completed in 1.5
to 2 hours, and the time of day was similar for all procedures across
drug conditions (ie, morning for pretesting, afternoon for posttraining).
The randomization code was broken after all completed analysis.
Figure 1 provides a schematic of the study design.

Fig 1. Schematic of study protocol and timing of testing.

Experimental session
Biomechanical measures of lower extremity strength and
reflexes, and clinical assessments were performed in the same order
during each session. Clinical assessments were obtained in the
beginning of each session and consisted of lower extremity Fugl-Meyer
scores, 6-minute walking distance (6MWD) at subject's normal
comfortable speed, and the fastest gait speeds over 10m.
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Biomechanical measures were obtained using an isokinetic
dynamometer (Biodexa) with an attached 6-degree-of-freedom load
cell.b For ankle measures, subjects were seated with the foot secured
in a footplate coupled to the load cell/Biodex, and the ankle and
Biodex motor axes were aligned,43 with the knee and hip at 0° and 75°
flexion, respectively. For knee measures, the Biodex and knee axes
were aligned with the shank secured to an attachment. Position and
velocity signals were recorded from Biodex transducers. All signals
were sampled at 1000Hz using data acquisition cards and custom
software.c Surface electromyographic activity was recorded by active
electrodesd on the paretic tibialis anterior (TA), medial gastrocnemius
(MG), and soleus. Signals were amplified (1000×) and filtered (20–
450Hz) before sampling. Torque and electromyographic signals were
measured during the following tasks: maximal volitional contractions
(MVCs) of knee flexion/extension and ankle plantarflexion/dorsiflexion;
passive paretic plantarflexor stretches; and passive and active-assist
stretch responses. To normalize electromyographic measures, the
maximum M wave was elicited through 1-millisecond stimuli applied to
the tibial or peroneal nerve to elicit a maximum response of paretic TA
and MG recordings.

Isometric MVC tasks
Three MVCs, each 3 to 5 seconds in duration, were performed
with ≥60 seconds of rest between trials. MVCs were tested in neutral
position (90° angle) for plantarflexion torques and at 30°
plantarflexion for dorsiflexion MVCs. Knee extension MVCs were
performed at 90° flexion and knee flexion MVCs at 30° flexion.

Passive plantarflexor stretch
Torques and electromyographic activity were measured during
passive, paretic plantarflexor stretch through controlled velocity
(ramp) ankle rotations from 30° to 0° at constant speeds (5, 30, 60,
90, or 120°/s). Each stretch was held for 10 seconds, and 3 stretch
reflexes were recorded at each speed with ≥60 seconds between trials.
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Passive and active-assist trials
Repeated MVCs during controlled ankle movements were
performed to assess the effects of SSRIs on combined volitional and
reflex behaviors during tasks that presumably increase brainstem 5-HT
release.22,23 These effects were assessed during 6 consecutive cycles of
passive and active-assist trials at 60°/s through the 30° range, with 3
seconds between rotations. Subjects relaxed during the first cycle
(passive cycle), followed by 3 repeated, concentric MVCs of paretic
dorsiflexors and plantarflexors during the second to fourth joint
rotations (active assist cycles), and then 2 subsequent passive cycles
(fifth and sixth cycles). Subjects were provided verbal cues to start
each MVC approximately 1 second before passive movement.

Data analysis
Custom MATLABe programs were used to analyze data. Torque
signals were low-pass filtered at 20Hz (fourth-order Butterworth filter
applied forward and backward). Torque and angle data during slow
(5°/s) stretches were fitted with sixth-order polynomials and
subtracted from faster trials to differentiate gravitational/passive
torques from reflex response.44 Electromyographic data were bandstop filtered at 55 to 65Hz. The root mean square electromyographic
activity was calculated using a 50-point moving window. The
electromyographic signal was normalized to the M-wave amplitude
from TA and MG obtained during each session. Recordings from the
soleus were nondetectable in 5 of 10 subjects, and only TA and MG
data are presented.
During MVC trials, peak torque was calculated as the average
torque at a maximum ±25-millisecond window, whereas agonist and
antagonist mean root mean square electromyographic activity was
determined using a 50-millisecond window at 50 milliseconds before
maximum torque. Antagonist muscle co-contraction was quantified by
dividing the antagonist muscle electromyographic activity by the
agonist electromyographic activity of the same muscle acting as an
antagonist (eg, MG co-contraction during plantarflexion was as
follows: [MG electromyographic activity during dorsiflexion MVC]/[MG
electromyographic activity during plantarflexion MVC]). During passive
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trials, stretch reflexes were quantified as the peak plantarflexor torque
during movements into dorsiflexion, with MG electromyographic
activity quantified at that torque, and averaged at each speed (30–
120°/s). For the passive and active-assist trials, analysis focused on
plantarflexor activity during dorsiflexion, with plantarflexion torque and
mean MG electromyographic activity calculated during the mid-50%
ramp of each active-assist cycle. Two passive and active-assist trials
were averaged.

Statistical analysis
SPSS version 19f was used for statistical analysis with α=.05. No
order effects were observed, and all data are compared between drug
conditions. For MVC testing, the percent increases (post/pre) in torque
and electromyographic activity were also compared between drug
conditions using paired t tests. Torques and electromyographic
responses during the passive and passive-active assist trials were
compared using repeated-measures analysis of variance with testing
condition (stretch velocity or trial number) and test condition (placebo
or SSRI) as main factors, with post hoc Tukey-Kramer or paired
comparisons. Pearson correlation coefficients were calculated to
evaluate correlations between SSRI-induced changes in torque, clinical
measures (Fugl-Myer, gait speed, 6MWD), and demographic
characteristics (age, time since stroke).

Results
Eleven subjects were eligible and initiated the study, although 1
felt “light-headed” 1 hour after SSRI ingestion and terminated
participation before posttesting, with no adverse effects on follow-up.
A total of 10 subjects (7 men) completed the entire experimental
protocol. The mean age ± SD of the participants was 57±10 years,
and the duration poststroke ± SD was 9.1±7.6 years. Patients
presented with either ischemic (n=6; 4 cortical, 2 subcortical) or
hemorrhagic (n=4) stroke (see table 1 for demographics). Four
individuals received SSRIs during the first test.
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Table 1. Demographics of 10 subjects who completed the study
Subject
No.

Sex

Age
(y)

Paresis
(R/L)

Pathology

Chronicity (y)

FM Score (1st
Pretest)

1

M

50

L

Ischemic

5

20

2

M

53

R

Ischemic

4

23

3

F

60

R

Hemorrhagic

4

18

4

M

71

R

Hemorrhagic

19

23

5

M

61

R

Hemorrhagic

11

16

6

F

35

R

Ischemic

8

16

7

M

50

R

Hemorrhagic

3

15

8

M

65

L

Ischemic

6

18

9

F

60

R

Ischemic

5

19

10

M

64

L

Ischemic

26

18

Abbreviations: F, female; FM, Fugl-Meyer; L, left; M, male; R, right.

Effect of SSRIs on isometric MVCs
A trend of increasing torques was observed with all paretic muscles
tested, but with substantial variability and no significant differences
after SSRI versus placebo conditions. For example, average
plantarflexor torque increased by 25%±45% after SSRI administration
(fig 2), but was not different after placebo administration (6%±15%;
P=.10). Nonsignificant differences in MG activity were also observed
(P=.10), with no differences in co-contraction (P=.45). Similar variable
changes were observed with dorsiflexion (29%±79% vs 2%±16%,
P=.28) and knee flexion torques (32%±56% vs –1%±33%, P=.07),
with no differences in paretic extensors (P>.30). Correlation analyses
revealed no significant relationships between baseline Fugl-Meyer
scores and increases in peak volitional torques after SSRIs (all P>.05).
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Fig 2. (A) Normalized (pre/post) MVC torques for lower limb muscle groups. Ankle
dorsiflexion, ankle plantarflexion, knee flexion, and knee extension torque. (B) Preand postplacebo and pre- and post-SSRI MG co-contraction (root mean square MG
electromyographic activity during flexion/root mean square MG electromyographic
activity during extension) during dorsiflexion MVCs. Error bars represent SEM.
Abbreviations: EMG, electromyographic; Mmax, M wave.

Effect of SSRIs on plantarflexor stretch reflexes
Reflex torques generated during passive stretch reflexes varied
with stretch velocity, with greater increases post-SSRIs (fig 3A).
Reflex torques increased from 30°/s to 120°/s trials in all test
conditions (fig 3B). With significant analysis of variance (P<.05), post
hoc testing indicated reflex torques at 90°/s trials were significantly
increased post-SSRI vs placebo (115%±49% vs 48%±47%, P=.03).
For 120°/s trials, differences in torque approached significance
(P=.08). Increases in stretch reflex torques post-SSRI were not
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correlated with Fugl-Meyer scores or other demographic or clinical
data.

Fig 3. Torque and MG electromyogram (EMG) during stretches of the plantar flexors.
(A) Joint angle, torque, and MG EMG are shown for a single representative subject
before and after SSRI. The torque in this figure is before subtraction of the passive
trials. (B) Grouped mean peak torque generated during the dorsiflexion perturbation
ramps (plantarflexor stretch) at different speeds. Error bars show the SEM. *P<.05.
Abbreviation: PF, plantarflexion.

Effect of SSRIs on passive and active-assist responses
The effects of SSRIs on stretch reflexes during superimposed
voluntary drive was tested with 6 consecutive stretch cycles, with
passive trials for the first, fifth, and sixth cycles, and volitional activity
during the second to fourth cycles (active assist). Despite attempts at
dorsiflexion during the second to fourth cycles, reflex torques were
observed at the end of the movement (fig 4A). As subjects relaxed
(fifth to sixth cycles), elevated electromyographic activity and torque
measures during rotations reflected the residual effect of volitional
drive on stretch reflex excitability, and were compared to the first
passive cycle. These effects were enhanced with SSRIs, with
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significant repeated-measures intervention for cycle and testing
condition. Post hoc comparisons suggested no differences during the
first passive cycle (P=.87) ( fig 4B). During the active-assist cycles
(cycles 2–4), plantarflexor reflexes were substantially greater postSSRI vs placebo (P=.08, .02, and .02, respectively). Specifically,
increases at the third to fourth cycles were approximately 2.5-fold
greater with SSRIs as compared with approximately 1.3-fold greater
with placebo. Elevated reflex responses appeared to carry-over into
subsequent passive cycles, with torque increases approaching
significance at the fifth cycle (P=.07) but no differences at the sixth
cycle.

Fig 4. (A) Passive and active-assist trials of a representative subject pre- and postSSRI. Gray vertical bars represent the middle 50% of the dorsiflexion ramp. The
increment in torque and the MG root mean square electromyographic activity that
occurred within this interval were calculated. (B) Grouped changes in torques during
these intervals across the 6 cycles. Data represent the mean values across 10 subjects
with error bars representing SEM. Abbreviation: EMG, electromyogram.
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Clinical measures
There were no differences in changes in 6MWD, fastest gait
speed, and lower limb Fugl-Meyer scores across test sessions, with
mean changes of less than 10% of baseline after either SSRIs or
placebo (fig 5).

Fig 5. Assessment of motor performance and gait pre- and postplacebo or pre- and
post-SSRI. (A) Distance covered during 6-minute walk. (B) Gait speed during fast
walking. (C) Lower limb Fugl-Meyer score. Bars represent the average values across
all subjects, and error bars show SEM.

Discussion
In the present study, SSRIs demonstrated a significant increase
in plantarflexor stretch reflexes in patients poststroke at faster
perturbation speeds, which was enhanced with superimposed
voluntary drive. No significant increase in any measure of strength or
functional outcomes was observed after SSRIs. Increased spasticity
has not been reported previously in patients poststroke after SSRI
administration, and only studies in patients with SCI have indicated
increased SSRI-induced spasticity.

Effects of SSRIs on stretch reflex excitability
Increased stretch reflexes with enhanced 5-HT transmission are
consistent with results from animal models with increased descending
5-HT after decerebration, raphe electrical stimulation,45 or spinalization
with 5-HT precursors.46 We believe increased 5-HT was the likely
primary determinant of increased velocity-dependent stretch reflexes
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observed here, consistent with clinical measures of increased spasticity
in subjects with SCI.30,31 Greater increases in stretch reflexes were
also observed during the active-assist cycles, with increased activity at
speeds (60°/s) at which little effect was seen in the “passive-only”
trials. We believe this increased spasticity may be related to elevated
descending 5-HT pathways during repetitive rhythmic MVCs,22 which
provided a greater substrate for action of the SSRIs. The resulting 5HT modulation of spinal circuits24 could result in depolarization of
motoneurons and selected interneurons and amplification of persistent
inward currents,25, 47,48 thereby increasing motor output with specific
afferent inputs.

Minimal changes in single MVCs or clinical assessments
The absence of significant gains in MVCs with little co-activation
or lack of improvements in functional measures was surprising given
the published data in upper extremity studies of patients
poststroke.17,26 One explanation may be assessment of lower extremity
function in the present study, where direct cortical projections to lower
versus upper extremity motor pools in humans are more limited, such
that increased motor cortical excitability may not sufficiently increase
descending commands to increase peak force output. However,
patients with incomplete SCI demonstrate increases in strength,30
suggesting that differences in tested populations may also contribute.
Conversely, another explanation to account for nonsignificant
increases in MVCs is the use of discrete single contractions of a limited
duration, which may cause a more limited increase in activity of
brainstem 5-HT neurons.49,50 Single MVCs may not have sufficiently
increased 5-HT release, thus providing a more limited response with
SSRIs. Indeed, greater changes in upper limb motor function in
patients poststroke are observed with brief bouts of task practice, and
that may influence the present results.
A related finding was the minimal improvements in walking
function. While locomotion is associated with increased 5-HT activity,
the nonsignificant increases in strength with significant gains in
spasticity could have limited functional performance. More detailed
biomechanical and electromyographic analyses during walking after
SSRIs are necessary to identify specific locomotor changes,51
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particularly to indicate whether altered muscle activity contributed to
changes in walking function. Regardless, the present data are
consistent with selected studies in animal models52 and humans of
neurologic injury (SCI)51 indicating no immediate improvements in
locomotion function with single-dose enhancement of 5-HT
transmission. These findings are of clinical interest because previous
data suggest improvements in motor function after prolonged SSRI
use, although greater changes were observed in upper versus lower
limbs.19 Further study is certainly necessary to address the potential
effects of SSRIs on lower limb function poststroke in single or repeated
doses and combined with rehabilitation.

Study limitations
The main limitation of the present work is the small sample size.
Sample estimates were, however, based on published power analyses
on the effects of single-dose SSRI on patients with neurologic injury,30
although the present sample was sufficient to observe differences in
spastic responses. These relative changes suggest “positive” UMN
signs may be influenced more in the lower extremity poststroke with
SSRIs than weakness. Further studies are necessary to evaluate what
clinical or demographic factors determine responsiveness to SSRIs.
An additional limitation is the effects of multiple testing
procedures on patient performance and potential fatigue during
testing. The use of a randomized blinded trial design with identical
order of procedures was necessary to ensure this limitation did not
selectively alter outcomes, and this limitation may be difficult to
overcome in these and similar studies.
Finally, the present study was limited to the use of only singledose effects of escitalopram as opposed to other SSRIs that have been
tested. The single-dose effects were studied to minimize habituation to
the tested agents,27,29 although greater effects on motor function,
including both volitional and reflex behaviors, may be enhanced with
prolonged doses.34 Further, escitalopram was chosen because of
potential increased clinical use given its greater efficacy for depressive
disorders.53 Whether similar effects would be observed with other 5-HT
agents is not clear, although previous data suggest a similarity in
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changes in motor excitability or performance with various
SSRIs.17 and 20

Conclusions
In summary, single doses of SSRIs did not enhance
performance of lower limb voluntary tasks in chronic stroke subjects
but rather increased spastic motor activity. This effect was enhanced
during repetitive volitional tasks. Increased spastic behaviors with little
improvement in function may be considered a potential adverse effect
of SSRIs when prescribing these agents to chronic poststroke subjects
for depressive symptoms. The lack of improvements in lower limb
function with SSRIs may also be important given the results of recent
positive trials on upper limb function, and suggests that more work
should be done to investigate their global effects.
Suppliers
a. Biodex; Biodex Medical Systems, Inc.
b. Six-degree-of-freedom load cell; ATI Industrial Automation.
c. Custom software and NI-DAQ; National Instruments.
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